Acquisition of FDA-Approved Retinal Therapy Signals IMVIONIX's Entry as a Commercial-Stage Ophthalmology Company

收购FDA批准的视网膜疗法标志着IMVIONIX正式步入商业化阶段的眼科公司行列

PEACHTREE CORNERS, Ga.

佐治亚州桃树角

,

，

Nov. 10, 2026

2026年11月10日

/PRNewswire/ -- IMVIONIX Inc., a privately held biotechnology company dedicated to advancing the delivery of retinal therapies, today announced that it has acquired exclusive commercial rights to BEOVU

/美通社/ -- 专注于推进视网膜疗法递送的私人生物技术公司IMVIONIX Inc.今日宣布，已收购BEOVU的独家商业化权利

®

®

(brolucizumab-dbll) in the United States and Canada from Novartis. This acquisition marks the official commercial launch of IMVIONIX and represents the company's first strategic transaction in its mission to improve vision by advancing the reach of retinal therapies where unmet needs for patients and physicians persist..

（布罗鲁珠单抗-dbll）在美国和加拿大的权益，该交易来自诺华。此次收购标志着IMVIONIX正式商业化上市，也代表该公司在使命驱动下的首次战略交易，旨在通过扩大视网膜疗法的可及性，改善视力，满足患者和医生尚未被满足的需求。

'We founded IMVIONIX because we believe there are proven retinal therapies where physicians and patients can further benefit from the focus and reach of a dedicated retina company,' said Rick Eiswirth, Founder and Chief Executive Officer of IMVIONIX. 'Building on the strong foundation already established for BEOVU.

IMVIONIX创始人兼首席执行官Rick Eiswirth表示：“我们创立IMVIONIX，是因为我们相信，在已有确证疗效的视网膜疗法领域，医生和患者能够从一家专注于视网膜领域的公司所具备的专业聚焦与广泛覆盖中进一步获益。”“我们将依托BEOVU已建立的坚实基础继续发展。”

®

®

, this acquisition exemplifies the type of opportunity IMVIONIX was built to pursue.' IMVIONIX believes that an organization with deep relationships in the retina community is best positioned to expand the reach of such therapies and bring them to the physicians and patients who may potentially benefit most.

“此次收购正是IMVIONIX创立之初旨在追求的机遇典范。”IMVIONIX认为，在视网膜领域拥有深厚关系的组织最有利于扩大此类疗法的覆盖范围，并将其带给可能获益最大的医生和患者。

'We are excited to bring our focused commercial expertise to bear on behalf of the retina community,' Eiswirth continued..

“我们很高兴能够将我们专注的商业专业知识应用于代表视网膜社群，”艾斯沃斯继续说道。

BEOVU

BEOVU

®

®

is approved in both the United States and Canada for the treatment of Neovascular (Wet) Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME), two leading causes of irreversible vision loss. Under the terms of the agreement, IMVIONIX will become the marketing authorization holder for BEOVU.

该药已在美国和加拿大获批，用于治疗新生血管性（湿性）年龄相关性黄斑变性（AMD）和糖尿病性黄斑水肿（DME），这两种疾病是导致不可逆视力丧失的主要原因。根据协议条款，IMVIONIX 将成为 BEOVU 的上市许可持有人。

®

®

in the United States and Canada. Financial terms of the transaction were not disclosed.

在美国和加拿大。交易的财务条款未予披露。

IMVIONIX was founded in 2025 by the former executive management team of Alimera Sciences, Inc. — Rick Eiswirth, Jason Werner, Todd Wood, and Elliot Maltz — in collaboration with Caligan Partners LP and Velan Capital. The founding team brings a combined 60 years of expertise in ophthalmology.

IMVIONIX 由 Alimera Sciences, Inc. 的前核心管理团队——Rick Eiswirth、Jason Werner、Todd Wood 和 Elliot Maltz——与 Caligan Partners LP 及 Velan Capital 合作，于 2025 年创立。创始团队在眼科领域拥有合计 60 年的专业经验。

'The acquisition of BEOVU

收购 BEOVU

®

®

marks an important first step in building IMVIONIX into a company that focuses on serving retina specialists and their patients,' Eiswirth added. 'BEOVU

“标志着将 IMVIONIX 打造为一家专注于服务视网膜专科医生及其患者的公司的重要第一步，”Eiswirth 补充道。“BEOVU

®

®

has proven efficacy in two significant retinal conditions, and we believe it is well positioned to deliver additional meaningful value to the retina community. This acquisition reflects our core mandate — identifying therapies that align with our retina focused investment and commercialization platform.

已在两种重大视网膜疾病中证实疗效，我们相信其有能力为视网膜领域社区创造更多显著价值。此次收购体现了我们的核心使命——识别与我们专注于视网膜的投资和商业化平台相契合的疗法。

Our team has a proven track record of bringing ophthalmic therapies to market and we are well capitalized to execute on our mission.'.

我们的团队在推动眼科疗法上市方面拥有经证实的良好记录，且资金充足，能够有效执行我们的使命。

About IMVIONIX

关于 IMVIONIX

IMVIONIX is a privately held ophthalmology biotechnology company focused on advancing the delivery of retinal therapies. Founded in 2025 in collaboration with Caligan Partners LP and Velan Capital, IMVIONIX identifies, develops, and commercializes promising treatments that retina patients and physicians may need but cannot reach.

IMVIONIX 是一家私营眼科生物技术公司，专注于推进视网膜疗法的递送技术。IMVIONIX 于 2025 年与 Caligan Partners LP 和 Velan Capital 合作创立，致力于识别、开发并商业化那些视网膜患者和医生亟需但目前难以获取的潜在疗法。

The acquisition of U.S. and Canadian rights to BEOVU® was supported by Caligan Partners LP and its investors.

BEOVU®在美国和加拿大的权益收购得到了Caligan Partners LP及其投资者的支持。

.

。

The company was founded by Rick Eiswirth, Jason Werner, Todd Wood, and Elliot Maltz who bring deep experience building ophthalmology brands and a proven track record in retinal disease. Together they successfully commercialized retinal therapies targeting unmet needs and helped improve patient outcomes.

该公司由里克·艾斯沃斯（Rick Eiswirth）、杰森·沃纳（Jason Werner）、托德·伍德（Todd Wood）和埃利奥特·马尔茨（Elliot Maltz）共同创立，他们在眼科品牌建设方面拥有深厚经验，并在视网膜疾病领域有着经证实的卓越业绩。他们携手成功实现了针对未满足需求的视网膜疗法的商业化，并帮助改善了患者的治疗结果。

For more information, please visit .

更多信息，请访问。

www.imvionix.com

www.imvionix.com

.

。

About BEOVU

关于 BEOVU

®

®

(brolucizumab-dbll)

（布罗鲁珠单抗-dbll）

BEOVU

BEOVU

®

®

(brolucizumab-dbll) is a humanized single-chain antibody fragment (scFv) VEGF inhibitor administered by intravitreal injection. BEOVU

（布罗鲁珠单抗-dbll）是一种人源化单链抗体片段（scFv）VEGF抑制剂，通过玻璃体内注射给药。BEOVU

®

®

is indicated in both the United States and Canada for the treatment of Neovascular (Wet) Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME), two leading causes of irreversible vision loss.

在美国和加拿大均获批用于治疗新生血管性（湿性）年龄相关性黄斑变性（AMD）和糖尿病性黄斑水肿（DME），这两种疾病是导致不可逆视力丧失的主要原因。

Important safety information for BEOVU

BEOVU 的重要安全信息

®

®

includes risks of endophthalmitis, retinal detachment, retinal vasculitis, and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, increases in intraocular pressure, and potential risk of arterial thromboembolic events. Patients should be instructed to report any symptoms suggestive of endophthalmitis, retinal detachment, or any change in vision without delay..

包括眼内炎、视网膜脱离、视网膜血管炎和/或视网膜血管阻塞的风险，通常伴有眼内炎症、眼压升高，以及潜在的动脉血栓栓塞事件风险。应指导患者立即报告任何提示眼内炎、视网膜脱离的症状或任何视力变化。

Please see full Prescribing Information for BEOVU

请参阅 BEOVU 的完整处方信息

®

注册商标符号

at

在

www.beovu.com

www.beovu.com

.

。

BEOVU® is a registered trademark of Novartis AG and is used under license.

BEOVU® 是诺华公司（Novartis AG）的注册商标，经许可使用。

Forward-Looking Statements

前瞻性陈述

This press release contains forward-looking statements within the meaning of applicable securities laws. These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied. Forward-looking statements are based on management's current expectations and are subject to change.

本新闻稿包含适用证券法律定义下的前瞻性陈述。这些陈述涉及已知和未知的风险与不确定性，可能导致实际结果与明示或暗示的结果存在重大差异。前瞻性陈述基于管理层当前的预期，并可能发生变化。

IMVIONIX undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances after the date hereof, except as required by law..

IMVIONIX 不承担任何义务，以更新任何前瞻性陈述来反映在本声明日期之后的新信息、事件或情况，除非法律另有要求。

SOURCE IMVIONIX

来源 IMVIONIX